for clinical characteristics). For all panels, mRNA levels were determined using absolute quantification and normalized to GAPDH mRNA levels. Error bars depict SEM of 2 technical replicates for each patient sample. Table 1 ) were serially harvested pre-decitabine and at serial points following administration of decitabine. LINE-1 methylation was used as a surrogate for global methylation and was Patients were separated into clinically responsive (left, n = 7) and non-responsive (right, n = 14)
Supplemental
cohorts based on standard evaluation criteria (see Table 1 TAP1 levels were determined using relative quantification and normalized to 18S rRNA. For all panels, p-values were determined using Wilcoxon matched-pairs signed rank test.
Supplemental Figure 7 . Effect of decitabine monotherapy on NY-ESO-1 and MAGEA protein levels. Immunoblotting analysis of NY-ESO-1 and MAGEA protein levels in serial peripheral blood samples harvested from 3 Cohort "A" patients and 8 Cohort "C" patients. -actin was used as a loading control and OVCAR cells exposed to decitabine acted as a positive control ("+").
